Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation

Blood. 2005 Apr 1;105(7):2991-4. doi: 10.1182/blood-2004-09-3715. Epub 2004 Dec 16.

Abstract

Systemic autoimmune disease (AID) can be controlled with conventional therapies in most patients. However, relapses are common, leading to progressive disability and premature death. Nonmyeloablative conditioning and allogeneic bone marrow transplantation (BMT) could be an effective treatment for severe AID, because of mild toxicity of the conditioning and the potential benefits of donor chimerism. We examined the effects of this treatment in experimental autoimmune arthritis. Our results demonstrate the induction of complete donor chimerism and significant suppression of disease activity. No clinical graft-versus-host disease (GVHD) was observed. The beneficial effects were most likely caused by the elimination of plasma cells producing pathogenic autoantibodies, because these antibodies disappeared rapidly after BMT. Although this type of treatment was effective in organ-specific T-cell-mediated AID, the present study provides convincing evidence that nonmyeloablative conditioning and allogeneic BMT can effectively treat severe B-cell-mediated AID with a systemic inflammatory component.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoantibodies / blood
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / therapy*
  • B-Lymphocytes / immunology*
  • Bone Marrow Transplantation / immunology*
  • Graft Survival / immunology
  • Histocompatibility Testing
  • Major Histocompatibility Complex / immunology*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Plasma Cells / immunology
  • Transplantation Conditioning*

Substances

  • Autoantibodies